FT-4202 at Higher Dose Safe and Helpful to Patients in Phase 1 Trial
News
A higher 600 mg daily dose of FT-4202, a potential disease-modifying oral treatment for sickle cell disease (SCD), was well-tolerated and safe, and improved several measures of red blood cell ... Read more